Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Shares Issued: 2013-2024

Historic Shares Issued for Viridian Therapeutics, Inc.\DE (VRDN) over the last 11 years, with Dec 2024 value amounting to $453.7 million.

  • Viridian Therapeutics, Inc.\DE's Shares Issued fell 96.91% to $11.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $84.8 million, marking a year-over-year decrease of 83.00%. This contributed to the annual value of $453.7 million for FY2024, which is 262.73% up from last year.
  • According to the latest figures from FY2024, Viridian Therapeutics, Inc.\DE's Shares Issued is $453.7 million, which was up 262.73% from $125.1 million recorded in FY2023.
  • Viridian Therapeutics, Inc.\DE's 5-year Shares Issued high stood at $453.7 million for FY2024, and its period low was $114.2 million during FY2021.
  • For the 3-year period, Viridian Therapeutics, Inc.\DE's Shares Issued averaged around $290.2 million, with its median value being $291.9 million (2022).
  • In the last 5 years, Viridian Therapeutics, Inc.\DE's Shares Issued slumped by 57.15% in 2023 and then soared by 262.73% in 2024.
  • Yearly analysis of 4 years shows Viridian Therapeutics, Inc.\DE's Shares Issued stood at $114.2 million in 2021, then surged by 155.49% to $291.9 million in 2022, then tumbled by 57.15% to $125.1 million in 2023, then skyrocketed by 262.73% to $453.7 million in 2024.